TRH Financial LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,906 shares of the biopharmaceutical company’s stock, valued at approximately $423,000.
Other large investors also recently made changes to their positions in the company. Fisher Asset Management LLC lifted its position in shares of Pfizer by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock worth $1,627,320,000 after purchasing an additional 1,158,147 shares during the period. California Public Employees Retirement System boosted its stake in shares of Pfizer by 5.3% in the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock valued at $1,004,428,000 after purchasing an additional 1,159,857 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Pfizer by 1.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 22,492,988 shares of the biopharmaceutical company’s stock valued at $808,173,000 after purchasing an additional 369,603 shares during the last quarter. Amundi Pioneer Asset Management Inc. increased its position in shares of Pfizer by 0.6% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 12,404,024 shares of the biopharmaceutical company’s stock worth $1,527,426,000 after buying an additional 77,664 shares during the period. Finally, California State Teachers Retirement System increased its position in shares of Pfizer by 0.4% during the third quarter. California State Teachers Retirement System now owns 10,332,260 shares of the biopharmaceutical company’s stock worth $371,238,000 after buying an additional 45,147 shares during the period. Institutional investors own 70.22% of the company’s stock.
PFE has been the topic of several recent analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Bank of America started coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target on the stock. Credit Suisse Group reiterated a “hold” rating and set a $41.30 price target on shares of Pfizer in a report on Wednesday, November 6th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Royal Bank of Canada initiated coverage on Pfizer in a research note on Monday, January 6th. They issued an “outperform” rating and a $46.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $43.41.
Pfizer stock opened at $40.34 on Wednesday. The company has a market capitalization of $224.19 billion, a PE ratio of 14.10, a PEG ratio of 4.24 and a beta of 0.65. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $44.56. The firm’s fifty day moving average is $39.14 and its 200 day moving average is $38.09. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The business had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. During the same period last year, the company posted $0.78 earnings per share. The business’s quarterly revenue was down 4.6% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a $0.38 dividend. The ex-dividend date of this dividend is Thursday, January 30th. This is an increase from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 annualized dividend and a dividend yield of 3.77%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.